EA200600687A1 - Композиции экзотрансферазы с3 clostridium botulinum и способы лечения метастазирования опухолей - Google Patents

Композиции экзотрансферазы с3 clostridium botulinum и способы лечения метастазирования опухолей

Info

Publication number
EA200600687A1
EA200600687A1 EA200600687A EA200600687A EA200600687A1 EA 200600687 A1 EA200600687 A1 EA 200600687A1 EA 200600687 A EA200600687 A EA 200600687A EA 200600687 A EA200600687 A EA 200600687A EA 200600687 A1 EA200600687 A1 EA 200600687A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
cell
clostridium botulinum
exotransferase
treatment
Prior art date
Application number
EA200600687A
Other languages
English (en)
Other versions
EA008824B1 (ru
Inventor
Лиза Маккеррахер
Дана Ласко
Original Assignee
Биоаксон Терапетик Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Биоаксон Терапетик Инк. filed Critical Биоаксон Терапетик Инк.
Publication of EA200600687A1 publication Critical patent/EA200600687A1/ru
Publication of EA008824B1 publication Critical patent/EA008824B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Insects & Arthropods (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Предоставлены фармацевтические композиции, каждая из которых содержит проникающий в клетку конъюгат слитого белка, содержащий полипептидный радикал переноса через клеточную мембрану и единицу экзотрансферазы С3 Clostridium botulinum или его функциональный аналог. Композиции могут использоваться для предотвращения или ингибирования бесконтрольной пролиферации, распространения и миграции метастазирующей опухолевой клетки при злокачественной опухоли млекопитающего. Каждая из композиций может влиять на два или большее количество событий, таких как пролиферация, миграция опухолевых клеток, ангиогенез и секреция металлопротеиназ.
EA200600687A 2003-09-29 2004-09-29 Композиции экзотрансферазы c3 clostridium botulinum и способы лечения метастазирования опухолей EA008824B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50616203P 2003-09-29 2003-09-29
US10/902,878 US20060134140A1 (en) 2001-04-12 2004-08-02 Compositions and methods for treating tumor spreading
PCT/CA2004/001763 WO2005030248A1 (en) 2003-09-29 2004-09-29 Clostridium botulinum c3 exotransferase compositions and methods for treating tumour spreading

Publications (2)

Publication Number Publication Date
EA200600687A1 true EA200600687A1 (ru) 2006-10-27
EA008824B1 EA008824B1 (ru) 2007-08-31

Family

ID=34396295

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200600687A EA008824B1 (ru) 2003-09-29 2004-09-29 Композиции экзотрансферазы c3 clostridium botulinum и способы лечения метастазирования опухолей

Country Status (13)

Country Link
US (4) US20060134140A1 (ru)
EP (1) EP1667709A4 (ru)
JP (1) JP2007506795A (ru)
KR (1) KR20070051766A (ru)
CN (1) CN1886154A (ru)
AU (1) AU2004275449A1 (ru)
BR (1) BRPI0414881A (ru)
CA (1) CA2539694A1 (ru)
EA (1) EA008824B1 (ru)
IL (1) IL174632A0 (ru)
NO (1) NO20061873L (ru)
NZ (1) NZ546253A (ru)
WO (1) WO2005030248A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442686B2 (en) 2001-04-12 2008-10-28 Bioaxone Therapeutique Inc. Treatment of macular degeneration with ADP-ribosyl transferase fusion protein therapeutic compositions
US7795218B2 (en) * 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20050220734A1 (en) * 2004-04-02 2005-10-06 Allergan, Inc. Therapy for melanin related afflictions
EP2168594B1 (en) 2004-09-23 2015-04-29 Toxcure, Inc. Treating neoplasms with neurotoxin
US8343929B2 (en) 2004-09-23 2013-01-01 Toxcure, Inc. Treating neoplasms with neurotoxin
MY142987A (en) * 2005-06-08 2011-02-14 Hayashibara Biochem Lab Solution for tissue adhesion prevention and method for tissue adhesion prevention
KR101047576B1 (ko) * 2006-11-16 2011-07-08 샌디스크 코포레이션 비휘발성 메모리의 소프트 프로그래밍에 있어서의 부스팅 제어
US8486467B1 (en) * 2007-09-20 2013-07-16 Albert G. Prescott Dermal filler and method of using same
JP2011513434A (ja) * 2008-03-07 2011-04-28 バイオアクソン セラピューティック インコーポレーテッド キメラＣ３様Ｒｈｏアンタゴニストによる骨治療
CA2889514A1 (en) 2008-11-26 2010-06-03 Toxcure, Inc. Treating neoplasms with neurotoxins
WO2010120931A2 (en) * 2009-04-14 2010-10-21 University Of Medicine And Dentistry Of New Jersey E2f as a target for treatment of hormone refractory prostate cancer
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
WO2012142328A2 (en) * 2011-04-12 2012-10-18 Ratner Buddy D Polymer microsphere compositions for localized delivery of therapeutic agents
RU2473367C1 (ru) * 2011-11-22 2013-01-27 Федеральное государственное унитарное предприятие "Научно-производственное объединение "Радиевый институт им. В.Г. Хлопина" Способ изготовления стента для радиационной терапии злокачественных опухолей желчного протока
CN108102945B (zh) * 2012-04-27 2021-08-24 山东新创生物科技有限公司 包含戈氏梭菌的衍生细菌菌株的组合物及其使用方法
GB201505347D0 (en) * 2015-03-27 2015-05-13 Salupont Consulting Ltd Sterilisation of s-nitrosothiols
JP7217700B2 (ja) 2016-09-13 2023-02-03 アラーガン、インコーポレイテッド 安定化非タンパク質クロストリジウム毒素組成物
TW201910511A (zh) * 2017-05-30 2019-03-16 美商維泰克斯製藥公司 C3融合蛋白以及其製備及使用方法
IT201800004220A1 (it) * 2018-04-05 2019-10-05 Dispositivo impiantabile per la somministrazione localizzata di farmaci, suoi usi e suo procedimento di fabbricazione.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
WO1997041232A1 (en) * 1996-04-26 1997-11-06 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
WO2000064478A1 (fr) * 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Medicaments destines a soigner et a prevenir les maladies du foie
US20020077283A1 (en) * 2000-09-08 2002-06-20 Sessa William C. Caveolin peptides and their use as therapeutics
DE10064195A1 (de) * 2000-12-22 2002-07-11 Migragen Ag Verwendung einer Zusammensetzung zur Stimulation des Nervenwachstums, zur Inhibition der Narbengewebsbildung und/oder Reduktion eines Sekundärschadens
CA2342970A1 (en) * 2001-04-12 2002-10-12 Lisa Mckerracher Fusion proteins
CA2367636C (en) * 2001-04-12 2010-05-04 Lisa Mckerracher Fusion proteins

Also Published As

Publication number Publication date
NO20061873L (no) 2006-06-29
CA2539694A1 (en) 2005-04-07
US20090142325A1 (en) 2009-06-04
EP1667709A4 (en) 2009-08-26
WO2005030248A1 (en) 2005-04-07
JP2007506795A (ja) 2007-03-22
EA008824B1 (ru) 2007-08-31
US20090285833A1 (en) 2009-11-19
CN1886154A (zh) 2006-12-27
KR20070051766A (ko) 2007-05-18
BRPI0414881A (pt) 2006-12-12
NZ546253A (en) 2009-03-31
US20080020000A1 (en) 2008-01-24
US20060134140A1 (en) 2006-06-22
AU2004275449A1 (en) 2005-04-07
EP1667709A1 (en) 2006-06-14
IL174632A0 (en) 2006-08-20

Similar Documents

Publication Publication Date Title
EA200600687A1 (ru) Композиции экзотрансферазы с3 clostridium botulinum и способы лечения метастазирования опухолей
DK1210411T3 (da) Sammensætninger og fremgangsmåder til forbedret celledyrkning
Jewett et al. Natural killer cells: diverse functions in tumor immunity and defects in pre-neoplastic and neoplastic stages of tumorigenesis
ATE500323T1 (de) Subtilisin-variante
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
DK82293A (da) Normalt sporulerende bacillus uden evne til at udskille subtilisin eller neutral protease, kulturer deraf og fremgangsmaade til fremstilling af heterologe proteiner dermed
AR025984A1 (es) Polipeptidos oligomericos de cadena simple
PT1282611E (pt) Fenilacetamidas substituidas e sua utilizacao como activadores da glucocinase
NO20070950L (no) Preparater og fremgangsmater for anvendelse av angiopoietinlignende-4-protein.
ATE265219T1 (de) Verwendung von cxcr4 antagonisten zur behandlung von krebs und autoimmunkrankheiten
NO990086L (no) Avkortete, l°selige tumornekrosefaktorreseptorer av type I og type II
EA201301350A1 (ru) Модифицированные полипептиды фактора vii и их применение
WO2005028436A3 (en) Thalidomide analogs as tnf-alpha modulators
ATE245437T1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
EA200101166A1 (ru) Ингибиторы металлопротеаз
DE60111570D1 (de) Isoindolin-1-on als glukokinaseaktivatoren
DE69433240D1 (de) Apoptosegen von wirbeltieren, zusammensetzungen und verwendungen
WO2001082870A3 (en) A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
FI960888A0 (fi) Protokadheriiniproteiineja ja niiden käyttö
DE69943020D1 (de) Tumorantigen verwendbar in der diagnose und therapie von prostata und dickdarm-krebs
ES2114548T3 (es) Procedimiento y composiciones para ensayos de complementacion de enzima utilizando la region omega de beta-galactosidasa.
DK11187A (da) Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem
Pratheeshkumar et al. Vernolide-A inhibits tumour specific angiogenesis by regulating proinflammatory cytokines, VEGF, MMPs and TIMP
SE8500470L (sv) Kompositioner for kosmetiskt, helso- och kroppsbevarande bruk
Bhat et al. PI metalloproteinases and L-amino acid oxidases from Bothrops species inhibit angiogenesis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU